Altimmune ((ALT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Altimmune, Inc. is currently conducting the RESTORE TRIAL, a Phase 2 study aimed at evaluating the efficacy and safety of Pemvidutide for treating Alcohol-Associated Liver Disease (ALD). This study is significant as it addresses a critical need for effective treatments for ALD, a condition with limited therapeutic options.
The intervention being tested is Pemvidutide, administered at a dose of 2.4 mg subcutaneously once a week. The purpose of this drug is to assess its potential benefits in managing ALD symptoms and improving liver function.
The study is designed as a multicenter, randomized, double-blind, placebo-controlled trial. Participants are randomly assigned to either the Pemvidutide group or a placebo group, with both participants and researchers unaware of the assignments to ensure unbiased results. The primary goal is to evaluate treatment efficacy.
The study began on June 16, 2025, with primary completion and estimated completion dates yet to be announced. The most recent update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical update could influence Altimmune’s stock performance positively if Pemvidutide shows promising results, potentially boosting investor confidence. The outcome may also impact the competitive landscape of ALD treatments, as successful trials could position Altimmune as a leader in this niche market.
The study is ongoing, with further details available on the ClinicalTrials portal.